{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:08:16Z","timestamp":1763035696467,"version":"3.40.4"},"reference-count":1,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2001]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Cyclosporine A and azathioprine are effective on mucocutaneous lesions in Adamantiades-Beh\u00e7et\u2019s disease. Mycophenolate mofetil (MMF) is a drug resembling their activity but with comparably negligible adverse reactions. &lt;i&gt;Objective:&lt;\/i&gt; A prospective clinical proof-of-principle study was conducted to investigate the effectiveness and toxicity of MMF in mucocutaneous Adamantiades-Beh\u00e7et\u2019s disease. &lt;i&gt;Methods:&lt;\/i&gt; Thirty patients were to be treated with MMF 2 g\/day p.o. for 6 months, in combination with prednisolone 30 mg\/day p.o. during the first month of treatment. Inefficacy was followed by an increase in MMF dose to 3 g\/day. The primary efficacy variable was the decrease in the disease activity index (DAI) according to a modified variant of the Iran Beh\u00e7et\u2019s Disease Dynamic Activity Measure system. &lt;i&gt;Results:&lt;\/i&gt; The study was interrupted due to inefficacy of the compound after the intermediate evaluation of the first 6 patients (aged 37.0 \u00b1 7.7 years with disease duration of 10.0 \u00b1 8.9 years) as required by the ethical committee. Although an improvement of the DAI from 5.2 \u00b1 3.5 to 1.3 \u00b1 0.5 was found after the first month of combination treatment, withdrawal of prednisolone led to quick relapses with a new index increase (3.0 \u00b1 3.5). The treatment was discontinued in 3 patients after 3 months, in 2 patients after 4 months and in another one after 5 months due to deterioration of the disease. Introduction of interferon \u03b1&lt;sub&gt;2a&lt;\/sub&gt; (3 \u00d7 9 million IU 3\u00d7\/week s.c.) in 3 patients decreased the activity index from 4.0 \u00b1 1.0 to 0.0 \u00b1 0.0. No adverse effects were detected under MMF treatment. &lt;i&gt;Conclusion:&lt;\/i&gt; MMF (2\u20133 g\/day) is unable to control the signs of mucocutaneous Adamantiades-Beh\u00e7et\u2019s disease.<\/jats:p>","DOI":"10.1159\/000051781","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T12:11:24Z","timestamp":1050408684000},"page":"322-324","source":"Crossref","is-referenced-by-count":50,"title":["Mycophenolate Mofetil Is Ineffective in the Treatment of Mucocutaneous Adamantiades-Beh\u00e7et\u2019s Disease"],"prefix":"10.1159","volume":"203","author":[{"given":"Y.D.","family":"Adler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Mansmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ch.C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2001,12,12]]},"reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.1001\/archderm.132.11.1323"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/51781","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/51781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:09:41Z","timestamp":1745467781000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000051781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":1,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2001,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000051781","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"type":"print","value":"1018-8665"},{"type":"electronic","value":"1421-9832"}],"subject":[],"published":{"date-parts":[[2001]]}}}